Literature DB >> 28785477

Challenges of Treating Acute Heart Failure in Patients with Chronic Obstructive Pulmonary Disease.

Jelena Čelutkienė1,2, Mindaugas Balčiūnas1,3, Denis Kablučko2, Liucija Vaitkevičiūtė4,5, Jelena Blaščiuk4, Edvardas Danila6,7.   

Abstract

Heart failure (HF) and chronic obstructive pulmonary disease (COPD) comorbidity poses substantial diagnostic and therapeutic challenges in acute care settings. The specific role of pulmonary comorbidity in the treatment and outcomes of cardiovascular disease patients was not addressed in any short- or long-term prospective study. Both HF and COPD can be interpreted as systemic disorders associated with low-grade inflammation, endothelial dysfunction, vascular remodelling and skeletal muscle atrophy. HF is regularly treated as a broader cardiopulmonary syndrome utilising acute respiratory therapy. Based on observational data and clinical expertise, a management strategy of concurrent HF and COPD in acute settings is suggested. Concomitant use of beta2-agonists and beta-blockers in a comorbid cardiopulmonary condition seems to be safe and effective.

Entities:  

Keywords:  Acute heart failure; acute respiratory therapy; beta-blockers; bronchodilators; chronic obstructive pulmonary disease

Year:  2017        PMID: 28785477      PMCID: PMC5494158          DOI: 10.15420/cfr.2016:23:2

Source DB:  PubMed          Journal:  Card Fail Rev        ISSN: 2057-7540


  58 in total

Review 1.  Natriuretic peptide testing in heart failure.

Authors:  Han-Na Kim; James L Januzzi
Journal:  Circulation       Date:  2011-05-10       Impact factor: 29.690

2.  Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD.

Authors:  Bianca Beghé; Alessia Verduri; Mihai Roca; Leonardo M Fabbri
Journal:  Eur Respir J       Date:  2013-04       Impact factor: 16.671

3.  Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity.

Authors:  John T Parissis; Chiara Andreoli; Nikolaos Kadoglou; Ignatios Ikonomidis; Dimitrios Farmakis; Ioanna Dimopoulou; Efstathios Iliodromitis; Maria Anastasiou-Nana; Mitja Lainscak; Giussepe Ambrosio; Alexandre Mebazaa; Gerasimos Filippatos; Ferenc Follath
Journal:  Clin Res Cardiol       Date:  2014-04-10       Impact factor: 5.460

4.  Are beta2-agonists responsible for increased mortality in heart failure?

Authors:  Margaret Bermingham; Eleanor O'Callaghan; Ian Dawkins; Saki Miwa; Shazzarina Samsudin; Kenneth McDonald; Mark Ledwidge
Journal:  Eur J Heart Fail       Date:  2011-08       Impact factor: 15.534

Review 5.  Mortality in COPD: Role of comorbidities.

Authors:  D D Sin; N R Anthonisen; J B Soriano; A G Agusti
Journal:  Eur Respir J       Date:  2006-12       Impact factor: 16.671

6.  Heart failure and respiratory hospitalizations are reduced in patients with heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure monitoring device.

Authors:  Jason S Krahnke; William T Abraham; Philip B Adamson; Robert C Bourge; Jordan Bauman; Greg Ginn; Fernando J Martinez; Gerard J Criner
Journal:  J Card Fail       Date:  2014-12-23       Impact factor: 5.712

Review 7.  Increased cardiovascular risk in patients with chronic obstructive pulmonary disease and the potential mechanisms linking the two conditions: a review.

Authors:  Kuldeepa Ghoorah; Anthony De Soyza; Vijay Kunadian
Journal:  Cardiol Rev       Date:  2013 Jul-Aug       Impact factor: 2.644

8.  Percent emphysema, airflow obstruction, and impaired left ventricular filling.

Authors:  R Graham Barr; David A Bluemke; Firas S Ahmed; J Jeffery Carr; Paul L Enright; Eric A Hoffman; Rui Jiang; Steven M Kawut; Richard A Kronmal; João A C Lima; Eyal Shahar; Lewis J Smith; Karol E Watson
Journal:  N Engl J Med       Date:  2010-01-21       Impact factor: 91.245

9.  Managed care and outcomes of hospitalization among elderly patients with congestive heart failure.

Authors:  H Ni; D J Nauman; R E Hershberger
Journal:  Arch Intern Med       Date:  1998-06-08

10.  Bronchodilator therapy in acute decompensated heart failure patients without a history of chronic obstructive pulmonary disease.

Authors:  Adam J Singer; Charles Emerman; Douglas M Char; J Thomas Heywood; J Douglas Kirk; Judd E Hollander; Richard Summers; Christopher C Lee; Janet Wynne; Lois Kellerman; William Frank Peacock
Journal:  Ann Emerg Med       Date:  2007-10-18       Impact factor: 5.721

View more
  6 in total

1.  Prognostic influence of prior chronic obstructive pulmonary disease in patients admitted for their first episode of acute heart failure: comment.

Authors:  Eftychios Siniorakis; Spyridon Arvanitakis; Vaia Derveni; Dimitrios Veldekis; Sotiria Limberi
Journal:  Intern Emerg Med       Date:  2018-05-03       Impact factor: 3.397

2.  Alternative signaling pathways from IGF1 or insulin to AKT activation and FOXO1 nuclear efflux in adult skeletal muscle fibers.

Authors:  Sarah J Russell; Martin F Schneider
Journal:  J Biol Chem       Date:  2020-08-31       Impact factor: 5.157

3.  Active screening for COPD among hospitalized smokers - a feasibility study.

Authors:  Katarzyna Mycroft; Piotr Korczynski; Piotr Jankowski; Mikolaj Kutka; Olga Zelazna; Marcin Zagaja; Kornelia Wozniczko; Urszula Szafranska; Lukasz Koltowski; Grzegorz Opolski; Rafal Krenke; Katarzyna Gorska
Journal:  Ther Adv Chronic Dis       Date:  2020-12-14       Impact factor: 5.091

Review 4.  Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure.

Authors:  Joyce N Njoroge; John R Teerlink
Journal:  Circ Res       Date:  2021-05-13       Impact factor: 17.367

Review 5.  Resolving the Ionotropic P2X4 Receptor Mystery Points Towards a New Therapeutic Target for Cardiovascular Diseases.

Authors:  Bruno Bragança; Paulo Correia-de-Sá
Journal:  Int J Mol Sci       Date:  2020-07-15       Impact factor: 5.923

6.  Reduction of mortality and predictions for acute myocardial infarction, stroke, and heart failure in Brazil until 2030.

Authors:  Camila Alves Dos Santos Siqueira; Dyego Leandro Bezerra de Souza
Journal:  Sci Rep       Date:  2020-10-20       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.